Elegen Secures $35M in Series B for DNA Synthesis
Key Highlights $35 million Series B round led by Triatomic Capital, featuring GSK and John Ballantyne. Investment to expand ENFINIA™…
Browsing Tag
Vijay Pande
2 posts
Genesis Therapeutics Closes Oversubscribed $200 Million Series B Financing
Genesis Therapeutics, a pioneer in integrating artificial intelligence (AI) technologies for the development of innovative medicines for patients…